Xilio Therapeutics, Inc. (XLO)
$9.00-$0.01 (-0.11%) Today
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 7 | 35,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
21 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Akintunde Olatokumbo Bello | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| James Samuel Shannon | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
 Daniel J. Curran | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| Yuan Xu | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
 Robert W. Ross | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| Sara Bonstein | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| Aoife Brennan | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| Cheryl R. Blanchard | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| James Samuel Shannon | Open-market purchase | Common Stock | 5,000 | $8.79 | $44K | |
| GILEAD SCIENCES, INC. - 10% Owner | Open-market purchase | Prefunded Warrants (right to buy) | 3,739,000 | $7.49 | $2.00M | |
| Katarina Luptakova - Officer | Option exercise | Common Stock | 16,625 | - | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 451,885 | $0.00 | - | |
| Katarina Luptakova - Officer | Option exercise | Restricted Stock Units | 16,625 | $0.00 | - | |
| Kevin M. Brennan - Officer | Option exercise | Common Stock | 5,000 | - | - | |
| Kevin M. Brennan - Officer | Open-market sale | Common Stock | 1,826 | $9.00 | $1K | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 95,221 | $0.00 | - | |
| Kevin M. Brennan - Officer | Option exercise | Restricted Stock Units | 5,000 | $0.00 | - | |
| Christopher James Frankenfield - Officer | Option exercise | Common Stock | 19,375 | - | - | |
| Christopher James Frankenfield - Officer | Open-market sale | Common Stock | 7,030 | $9.00 | $5K | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 668,789 | $0.00 | - | |
| Christopher James Frankenfield - Officer | Option exercise | Restricted Stock Units | 19,375 | $0.00 | - | |
| Rene Russo - Officer | Option exercise | Common Stock | 44,250 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 1,500,258 | $0.00 | - | |
| Rene Russo - Officer | Option exercise | Restricted Stock Units | 44,250 | $0.00 | - | |
| GILEAD SCIENCES, INC. - 10% Owner | Other | Prefunded Warrants (right to buy) | 13,335,000 | $10.50 | $10.00M | |
| GILEAD SCIENCES, INC. - 10% Owner | Other | Series B Warrants (right to buy) | 13,335,000 | $0.00 | - | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 131,700 | $0.00 | - | |
| Kevin M. Brennan - Officer | Derivative | Stock Option (right to buy) | 55,000 | - | - | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 55,000 | - | - | |
| Kevin M. Brennan - Officer | Derivative | Stock Option (right to buy) | 25,000 | - | - | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 25,000 | - | - | |
| Kevin M. Brennan - Officer | Derivative | Stock Option (right to buy) | 20,000 | - | - | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 20,000 | - | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 625,000 | $0.00 | - | |
| Katarina Luptakova - Officer | Derivative | Stock Option (right to buy) | 44,210 | - | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 44,210 | - | - | |
| Katarina Luptakova - Officer | Derivative | Stock Option (right to buy) | 15,000 | - | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 15,000 | - | - | |
| Katarina Luptakova - Officer | Derivative | Stock Option (right to buy) | 35,000 | - | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 35,000 | - | - | |
| Katarina Luptakova - Officer | Derivative | Stock Option (right to buy) | 25,000 | - | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 25,000 | - | - | |
| Katarina Luptakova - Officer | Derivative | Stock Option (right to buy) | 106,000 | - | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 106,000 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 2,075,000 | $0.00 | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 239,703 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 239,703 | - | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 473,334 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 473,334 | - | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 135,134 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 135,134 | - | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 50,041 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 50,041 | - | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 100,000 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 100,000 | - | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 150,000 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 150,000 | - | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 350,000 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 350,000 | - | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 700,000 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 700,000 | - | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 925,000 | $0.00 | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 155,090 | - | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 155,090 | - | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 23,786 | - | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 23,786 | - | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 37,296 | - | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 37,296 | - | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 20,000 | - | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 20,000 | - | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 117,000 | - | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 117,000 | - | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 150,000 | - | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 150,000 | - | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 300,000 | - | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 300,000 | - | - | |
| GILEAD SCIENCES, INC. - 10% Owner | Open-market purchase | Common Stock | 1,759,978 | $14.56 | $1.83M | |
| GILEAD SCIENCES, INC. - 10% Owner | Open-market purchase | Prefunded Warrants (right to buy) | 6,092,816 | $14.56 | $6.34M | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 26,000 | $0.00 | - |
Xilio Therapeutics, Inc. (XLO) had 7 insider filings in the last 90 days, with the most recent on 2026-06-12. The full record for XLO runs to 21 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of XLO were filed in the last 90 days. 4 purchases are on record for this company.
No insider sales of XLO were filed in the last 90 days. 2 sales are on record for this company.
This page tracks XLO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add XLO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$XNDUXanadu Quantum Technologies Ltd
$XPEPXAMG Pantheon Fund, LLC
$XPEVXPENG INC.
$XRTXXORTX Therapeutics Inc.
$XSLLUXsolla SPAC 1
$XSPIXStepStone Private Venture & Growth Fund
$XTERUKarman Line Acquisition Corp.
$XTNDXtend AI Robotics, Inc.
$XXCXINXU COPPER INDUSTRY TECHNOLOGY Ltd
$XXITwenty One Capital, Inc.Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.